Inolimomab

Drug Profile

Inolimomab

Alternative Names: Anti-CD25 monoclonal antibody B-B10; Anti-interleukin-2 receptor monoclonal antibody B-B10; B-B10; BT-563; Leukotac

Latest Information Update: 19 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator OPi
  • Developer Jazz Pharmaceuticals plc
  • Class Monoclonal antibodies
  • Mechanism of Action Interleukin 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Graft-versus-host disease

Most Recent Events

  • 12 Oct 2017 Elsalys Biotech acquires worldwide development and commercialisation rights of inolimomab from Jazz pharmaceuticals
  • 24 Sep 2015 EUSA Pharma completes a phase III trial in Graft-versus-host disease in Belgium and France (EudraCT2007-005009-24) prior to September 2015
  • 28 Apr 2015 Phase-III development is ongoing in Belgium and France
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top